Literature DB >> 19623435

The use of an antagonist 5-HT2a/c for depression and motor function in Parkinson' disease.

Antonio Luiz dos Santos Werneck1, Ana Lucia Rosso, Maurice Borges Vincent.   

Abstract

OBJECTIVE: To test the ability of a 5HT2a/c (trazodone) antagonist, to improve depression and motor function in Parkinson' disease (PD).
METHOD: Twenty PD patients with and without depression were randomly assigned to receive trazodone (group 1) or not (group 2). They were evaluated through UPDRS and Hamilton Depression Rating Scale (HAM-D).
RESULTS: For the UPDRS the mean score of group 2 was 33.1 +/- 19.7 and 37.1 +/- 18.0 at the end. For the group 1, the corresponding scores were 31.4 +/- 11.3 and 25.9 +/- 13.7. The variations in the Mann-Whitney test were 0.734 at the initial moment and 0.208 at the final moment. The variation in the comparison of the initial moment with the final moment was 0.005 providing statistical significance. For the HAM-D, the mean score went up 4 points in group 2, contrary to a 5.5 points decrease in group 1.
CONCLUSION: Data analysis shows that this agent significantly improves depression, but the motor function improved only in the depressed patients. Because of the known anti-dopaminergic property of the 5-HT2c receptors, a possible approach for depression in PD could be the use of 5-HT2c antagonists, similarly to the use of atypical neuroleptics in case of psychotic symptoms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19623435     DOI: 10.1590/s0004-282x2009000300007

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  14 in total

Review 1.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 2.  Neuropsychiatric Issues in Parkinson's Disease.

Authors:  Jeffrey W Cooney; Mark Stacy
Journal:  Curr Neurol Neurosci Rep       Date:  2016-05       Impact factor: 5.081

3.  In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Authors:  Agostinho Lemos; Rita Melo; Antonio Jose Preto; Jose Guilherme Almeida; Irina Sousa Moreira; Maria Natalia Dias Soeiro Cordeiro
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

4.  Efficacy and tolerability of antidepressants in Parkinson's disease: A systematic review and network meta-analysis.

Authors:  Kelly A Mills; M Claire Greene; Rebecca Dezube; Carrie Goodson; Taruja Karmarkar; Gregory M Pontone
Journal:  Int J Geriatr Psychiatry       Date:  2017-12-13       Impact factor: 3.485

Review 5.  Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Mol Neurobiol       Date:  2012-01-06       Impact factor: 5.590

6.  Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.

Authors:  Adjia Hamadjida; Stephen G Nuara; Jim C Gourdon; Philippe Huot
Journal:  J Neural Transm (Vienna)       Date:  2017-12-15       Impact factor: 3.575

Review 7.  Treatment of the sleep disorders associated with Parkinson's disease.

Authors:  Lynn Marie Trotti; Donald L Bliwise
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

8.  A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's Disease.

Authors:  Patrick Roberts; Athan Spiros; Hugo Geerts
Journal:  Front Pharmacol       Date:  2016-02-02       Impact factor: 5.810

9.  Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response.

Authors:  Hugo Geerts; Athan Spiros; Patrick Roberts; Roy Twyman; Larry Alphs; Anthony A Grace
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

10.  A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease.

Authors:  Lakkhina Troeung; Sarah J Egan; Natalie Gasson
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.